Xencor, Inc.
NASDAQ:XNCR
Overview | Financials
Company Name | Xencor, Inc. |
Symbol | XNCR |
Currency | USD |
Price | 24.13 |
Market Cap | 1,688,665,660 |
Dividend Yield | 0% |
52-week-range | 15.31 - 27.24 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bassil I. Dahiyat Ph.D. |
Website | https://www.xencor.com |
An error occurred while fetching data.
About Xencor, Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD